Different angiotensin receptor blockers and incidence of diabetes: A nationwide population-based cohort study

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Chang, Chia Hsuin ^a,b,c   Chang, Yi Cheng ^b,c   Wu, Li Chiu ^a   Lin, Jou Wei ^b,c   Chuang, Lee Ming ^a,b,c   Lai, Mei Shu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Angiotensin receptor antagonists; Cohort studies; Diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIGITALIS GLYCOSIDE; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRBESARTAN; LOSARTAN; NITRIC ACID DERIVATIVE; OLMESARTAN; ORAL ANTIDIABETIC AGENT; TELMISARTAN; VALSARTAN; WARFARIN;

ADULT; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; ICD-9-CM; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; COHORT STUDIES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; REGISTRIES; TAIWAN;

EID: 84901623390     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-91     Document Type: Article

References (38)

1. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004, 30(6):498-505. 10.1016/S1262-3636(07)70147-7, 15671919.
2. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005, 46(5):821-826. 10.1016/j.jacc.2005.05.051, 16139131.
3. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369(9557):201-207. 10.1016/S0140-6736(07)60108-1, 17240286.
4. Jaques H. National Institure for Health and Clinical Excellence: NICE guideline on hypertension. Eur Heart J 2013, 34(6):406-408.
5. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, . CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003, 362(9386):759-766. 10.1016/S0140-6736(03)14282-1, 13678868, CHARM Investigators and Committees.
6. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, . SCOPE Study Group The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21(5):875-886. 10.1097/00004872-200305000-00011, 12714861, SCOPE Study Group.
7. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, , et al. NAVIGATOR Study Group Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362(16):1477-1490. NAVIGATOR Study Group.
8. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmieder RE, Schork MA, Stolt P, Viskoper R, Widimský J, Zanchetti A, . VALUE Trial Investigators Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006, 24(7):1405-1412. 10.1097/01.hjh.0000234122.55895.5b, 16794491, VALUE Trial Investigators.
9. Sawada T, Yamada H, Dahlof B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART study. Eur Heart J 2009, 30(20):2461-2469. 10.1093/eurheartj/ehp363, 19723695.
10. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, . Candesartan Antihypertensive Survival Evaluation in Japan Trial Group Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008, 51(2):393-398. 10.1161/HYPERTENSIONAHA.107.098475, 18172059, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.
11. Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H, . HIJ-CREATE Investigators Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009, 30(10):1203-1212. 10.1093/eurheartj/ehp101, 19346521, HIJ-CREATE Investigators.
12. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, . LIFE Study Group Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003. 10.1016/S0140-6736(02)08089-3, 11937178, LIFE Study Group.
13. Nishida Y, Takahashi Y, Nakayama T, Asai S. Comparative effect of angiotensin II type I receptor blockers and calcium channel blockers on laboratory parameters in hypertensive patients with type 2 diabetes. Cardiovasc Diabetol 2012, 11:53. 10.1186/1475-2840-11-53, 3416676, 22594344.
14. Ahmad MA, Kapur P, Khanam R, Akhtar M, Khan GH, Anwar MJ, Vohora D. Comparative effect of antihypertensive therapy on blood glucose level in hypertensive patients in an Indian population. Drug Res (Stuttg) 2014, 64:276-80.
15. Monami M, Ungar A, Lamanna C, Bardini G, Pala L, Dicembrini I, Marchi C, Vivarelli M, Zannoni S, Bartoli N, Marchionni N, Rotella CM, Mannucci E. Effects of antihypertensive treatments on incidence of diabetes: a case-control study. J Endocrinol Invest 2012, 35(2):135-138.
16. Song HF, Wang S, Li HW. Effect of angiotensin receptor blockers in the prevention of type 2 diabetes and cardiovascular events: a meta-analysis of randomized trials. Chin Med J (Engl) 2012, 125(10):1804-1810.
17. Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci 2011, 32(12):734-739. 10.1016/j.tips.2011.07.006, 3223326, 21880378.
18. van der Zijl NJ, Moors CC, Goossens GH, Blaak EE, Diamant M. Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms. Diabetes Obes Metab 2012, 14(7):586-595. 10.1111/j.1463-1326.2012.01559.x, 22226145.
19. Mallat SG. What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?. Cardiovasc Diabetol 2012, 11:32. 10.1186/1475-2840-11-32, 3351968, 22490507.
20. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43(5):993-1002. 10.1161/01.HYP.0000123072.34629.57, 15007034.
21. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109(7):2054-2057.
22. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005, 54(12):3442-3452. 10.2337/diabetes.54.12.3442, 16306360.
23. Chen CC, Chiang AN, Hsieh MH. Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?. Diabetes Res Clin Pract 2010, 90(2):e25-e26. 10.1016/j.diabres.2010.05.028, 20591527.
24. Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 2011, 29(2):3001-3007.
25. Danaei G, Rodriguez LA, Cantero OF, Logan R, Hernan MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res 2013, 22(1):70-96. 10.1177/0962280211403603, 3613145, 22016461.
26. Danaei G, Garcia Rodriguez LA, Fernandez Cantero O, Hernan MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 2013, 36(5):1236-1240. 10.2337/dc12-1756, 3631834, 23248196.
27. Muller-Fielitz H, Landolt J, Heidbreder M, Werth S, Vogt FM, Johren O, Raasch W. Improved insulin sensitivity after long-term treatment with AT1 blockers is not associated with PPARgamma target gene regulation. Endocrinology 2012, 153(3):1103-1115. 10.1210/en.2011-0183, 22253423.
28. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011, 342:d2234. 10.1136/bmj.d2234, 3082637, 21521728.
29. Barzilay JI, Gao P, Rydén L, Schumacher H, Probstfield J, Commerford P, Dans A, Ferreira R, Keltai M, Paolasso E, Yusuf S, Teo K, . TRANSCEND Investigators Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care 2011, 34(9):1902-1907. 10.2337/dc11-0545, 3161302, 21788624, TRANSCEND Investigators.
30. Saitoh Y, Hongwei W, Ueno H, Mizuta M, Nakazato M. Candesartan attenuates fatty acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Res Clin Pract 2010, 90(1):54-59. 10.1016/j.diabres.2010.06.005, 20667613.
31. Paolisso G1, Tagliamonte MR, Gambardella A, Manzella D, Gualdiero P, Varricchio G, Verza M, Varricchio M. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997, 11(5):307-312. 10.1038/sj.jhh.1000434, 9205938.
32. Shiuchi T1, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 2004, 43(5):1003-1010. 10.1161/01.HYP.0000125142.41703.64, 15037562.
33. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001, 38(4):884-890. 10.1161/hy1101.092970, 11641303.
34. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes 2004, 53(4):989-997. 10.2337/diabetes.53.4.989, 15047614.
35. Shiota A, Shimabukuro M, Fukuda D, Soeki T, Sato H, Uematsu E, Hirata Y, Kurobe H, Maeda N, Sakaue H, Masuzaki H, Shimomura I, Sata M. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice. Cardiovasc Diabetol 2012, 11:139. 10.1186/1475-2840-11-139, 3527353, 23137106.
36. Cobden DS, Niessen LW, Barr CE, Rutten FF, Redekop WK. Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes. Value Health 2010, 13(1):138-147. 10.1111/j.1524-4733.2009.00587.x, 19695005.
37. Ariza MA, Vimalananda VG, Rosenzweig JL. The economic consequences of diabetes and cardiovascular disease in the United States. Rev Endocr Metab Disord 2010, 11(1):1-10. 10.1007/s11154-010-9128-2, 20191325.
38. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011, 33(1):74-109. 10.1016/j.clinthera.2011.01.019, 21397776.